GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Whitehawk Therapeutics Inc (NAS:WHWK) » Definitions » PB Ratio

WHWK (Whitehawk Therapeutics) PB Ratio : 0.40 (As of Jul. 14, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Whitehawk Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-07-14), Whitehawk Therapeutics's share price is $1.91. Whitehawk Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was $4.74. Hence, Whitehawk Therapeutics's PB Ratio of today is 0.40.

The historical rank and industry rank for Whitehawk Therapeutics's PB Ratio or its related term are showing as below:

WHWK' s PB Ratio Range Over the Past 10 Years
Min: 0.31   Med: 1.19   Max: 4.01
Current: 0.4

During the past 5 years, Whitehawk Therapeutics's highest PB Ratio was 4.01. The lowest was 0.31. And the median was 1.19.

WHWK's PB Ratio is ranked better than
95.15% of 1279 companies
in the Biotechnology industry
Industry Median: 2.68 vs WHWK: 0.40

During the past 12 months, Whitehawk Therapeutics's average Book Value Per Share Growth Rate was 28.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.20% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Whitehawk Therapeutics was -31.20% per year. The lowest was -31.20% per year. And the median was -31.20% per year.

Back to Basics: PB Ratio


Whitehawk Therapeutics PB Ratio Historical Data

The historical data trend for Whitehawk Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whitehawk Therapeutics PB Ratio Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
- 3.70 1.98 0.47 1.48

Whitehawk Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.46 0.74 1.48 0.38

Competitive Comparison of Whitehawk Therapeutics's PB Ratio

For the Biotechnology subindustry, Whitehawk Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Whitehawk Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's PB Ratio falls into.


;
;

Whitehawk Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Whitehawk Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2025)
=1.91/4.739
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Whitehawk Therapeutics  (NAS:WHWK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Whitehawk Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Whitehawk Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Whitehawk Therapeutics Business Description

Traded in Other Exchanges
Address
2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Executives
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012